Literature DB >> 14990610

Metastatic conventional prostatic adenocarcinoma with diffuse chromogranin A and androgen receptor positivity.

M P Roudier1, L D True, R L Vessella, C S Higano.   

Abstract

Conventional prostate adenocarcinomas consist mainly of tumour cells of luminal immunophenotype with scattered neuroendocrine (NE) cells. NE cells are defined by chromogranin A (CGA) immunoreactivity. Unlike luminal cells, NE cells lack androgen receptor (AR) and prostate specific antigen (PSA) immunoreactivity. This report describes the first case of conventional prostate adenocarcinoma expressing CGA, PSA, and AR as determined by immunohistochemistry. A 64 year old man was diagnosed with conventional prostate adenocarcinoma in 1993; he underwent cystoprostatectomy in 1994; he developed an iliac bone metastasis in 1997 and mediastinal lymph node metastases in 1999. All specimens obtained during the progression of the disease consisted primarily of luminal cells with only scattered NE cells. In contrast, in samples of non-osseous and osseous metastases obtained at necropsy in 2001, greater than 80% of tumour cells were shown to express PSA, AR, and CGA. This suggests that during tumour progression, conventional prostate adenocarcinomas may evolve into an NE cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14990610      PMCID: PMC1770231          DOI: 10.1136/jcp.2003.010207

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  8 in total

1.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment.

Authors:  T Jiborn; A Bjartell; P A Abrahamsson
Journal:  Urology       Date:  1998-04       Impact factor: 2.649

2.  The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy.

Authors:  J L Krijnen; J F Bogdanowicz; C A Seldenrijk; P G Mulder; T H van der Kwast
Journal:  J Urol       Date:  1997-07       Impact factor: 7.450

3.  Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.

Authors:  Shinzou Isshiki; Koichiro Akakura; Akira Komiya; Hiroyoshi Suzuki; Naoto Kamiya; Haruo Ito
Journal:  J Urol       Date:  2002-02       Impact factor: 7.450

4.  Chromogranin A, an "on/off" switch controlling dense-core secretory granule biogenesis.

Authors:  T Kim; J H Tao-Cheng; L E Eiden; Y P Loh
Journal:  Cell       Date:  2001-08-24       Impact factor: 41.582

5.  Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation.

Authors:  J Jongsma; M H Oomen; M A Noordzij; W M Van Weerden; G J Martens; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Cancer Res       Date:  2000-02-01       Impact factor: 12.701

Review 6.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments.

Authors:  P A di Sant'Agnese
Journal:  Ann Oncol       Date:  2001       Impact factor: 32.976

7.  Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate.

Authors:  H Bonkhoff; U Stein; K Remberger
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone.

Authors:  Martine P Roudier; Lawrence D True; Celestia S Higano; Hubert Vesselle; William Ellis; Paul Lange; Robert L Vessella
Journal:  Hum Pathol       Date:  2003-07       Impact factor: 3.466

  8 in total
  1 in total

1.  Gene expression signatures of neuroendocrine prostate cancer and primary small cell prostatic carcinoma.

Authors:  Harrison K Tsai; Jonathan Lehrer; Mohammed Alshalalfa; Nicholas Erho; Elai Davicioni; Tamara L Lotan
Journal:  BMC Cancer       Date:  2017-11-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.